US50180M1080
US50180M1080
LB Pharmaceuticals Inc
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 1.2B EUR | 930.84M EUR | 707.12M EUR | 563.16M EUR |
Enterprise Value | 793.92M EUR | 652.95M EUR | 389.92M EUR | 316.56M EUR |
Valuation Multiples | ||||
Trailing P/E | 372.2x | -- | -- | -- |
Forward P/E | -7.2x | -- | -- | -- |
Price to Sales | -- | -- | -- | -- |
Price to Book | 3.21x | 2.8x | 1.87x | 1.87x |
EV/Revenue | -- | -- | -- | -- |
EV/EBITDA | -8.72x | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -4.49% | -8.9% | -7.13% | -4.81% |